CoChat

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection

Open access
Suah, Jing Lian, Tng, Boon Hwa, Tok, Peter Seah Keng, Husin, Masliyana, Thevananthan, Thevesh, Peariasamy, Kalaiarasu M., Sivasampu, Sheamini · 2022 · Emerging Microbes & Infections
Cited by 53

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Given emerging evidence of immune escape in the SARS-CoV-2 Omicron viral variant, and its dominance, effectiveness of heterologous and homologous boosting schedules commonly used in low-to-middle income countries needs to be re-evaluated. We conducted a test-negative design using consolidated national administrative data in Malaysia to compare the effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against SARS-CoV-2 infection in predominant-Delta and predominant-Omicron periods. Across both periods, homologous CoronaVac and AZD1222 boosting demonstrated lower effectiveness than heterologous boosting for CoronaVac and AZD1222 primary vaccination recipients and homologous BNT162b2 boosting. Broadly, marginal effectiveness was smaller by 40-50 percentage points in the Omicron period than the Delta period. Without effective and accessible second-generation vaccines, heterologous boosting using BNT162b2 for inactivated and vectored primary vaccination recipients is preferred.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/22221751.2022.2072773

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 6

  1. 10.1038/s41591-022-01704-7 · DOI · Paper page
  2. 10.1056/NEJMc2119358 · DOI · Paper page
  3. 10.1016/j.ijid.2022.03.028 · DOI · Paper page
  4. 10.1016/S0140-6736(21)02717-3 · DOI · Paper page
  5. 10.1016/S0140-6736(22)00094-0 · DOI · Paper page
  6. 10.2139/ssrn.4005130 · DOI

Cited by

See all 53

Metadata

Authors
Suah, J. L., Tng, B. H., Tok, P. S. K., Husin, M., Thevananthan, T., Peariasamy, K. M., & Sivasampu, S.
Venue
Emerging Microbes & Infections
Published
2022-05-23
Volume
11
Issue
1
Pages
1343-1345
ISSN
2222-1751 (ISSN-L)
OpenAlex
W4225283837
Cited by
53
References
3
FWCI
5.90
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection. https://app.cochat.ai/papers/10.1080/22221751.2022.2072773
The paper
Suah, J. L., Tng, B. H., Tok, P. S. K., Husin, M., Thevananthan, T., Peariasamy, K. M., & Sivasampu, S. (2022). Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection. Emerging Microbes & Infections. https://doi.org/10.1080/22221751.2022.2072773

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.